Bowman & Company’s DexCom DXCM Stock Holding History

Bowman & Company’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$614K	Sell	9,257 -2,211	-19%	-$143K	0.26%	76
2025 Q3	$772K	Sell	11,468 -98	-0.8%	-$7.75K	0.33%	67
2025 Q2	$1.01M	Buy	11,566 +4,512	+64%	+$354K	0.45%	59
2025 Q1	$482K	Buy	7,054 +1,535	+28%	+$125K	0.24%	78
2024 Q4	$429K	Sell	5,519 -1,158	-17%	-$85.7K	0.22%	78
2024 Q3	$448K	Buy	6,677 +753	+13%	+$61.8K	0.23%	76
2024 Q2	$672K	Buy	5,924 +527	+10%	+$66.6K	0.39%	69
2024 Q1	$749K	Buy	+5,397	New	+$678K	0.45%	66

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bowman & Company's DXCM Position: Q4 2025 in Review

Bowman & Company reduced its DexCom (DXCM) stake by 19% in Q4 2025, selling an estimated $143K and leaving 9,257 shares worth $614K. The position accounts for 0.26% of the portfolio, ranked #76.

Bowman & Company first reported a position in DXCM in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.01M in Q2 2025. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Bowman & Company held 9,257 shares of DexCom worth $614K as of Q4 2025.
Bowman & Company sold 2,211 DexCom shares in Q4 2025, an estimated $143K.
DexCom made up 0.26% of Bowman & Company's portfolio in Q4 2025, its #76 holding.
Bowman & Company first reported a position in DexCom in Q1 2024 and has held it in 8 quarters since.
Bowman & Company's DexCom position peaked at $1.01M in Q2 2025.
921 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Bowman & Company's 13F filing for Q4 2025, filed 23 Jan 2026.